Who are Jesduvroq's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Enaroy, Musredo, Allomaleic Acid, Butanedioic Acid, VADADUSTAT.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/daprodustat.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Jesduvroq — Competitive Intelligence Brief

Jesduvroq (DAPRODUSTAT) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]. Area: Hematology.

marketed Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] Egl nine homolog 1 Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Jesduvroq (DAPRODUSTAT) — GSK. Jesduvroq works by activating hypoxia-inducible factor prolyl hydroxylase inhibitors, which increases the production of erythropoietin, a hormone that stimulates red blood cell production.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Jesduvroq TARGET	DAPRODUSTAT	GSK	marketed	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]	Egl nine homolog 1	2023-01-01
Enaroy	ENARODUSTAT	Japan Tabacco	marketed		Egl nine homolog 1
Musredo	MOLIDUSTAT	BAYER YAKUHIN, Ltd	marketed		Egl nine homolog 1
Allomaleic Acid	FUMARIC ACID		marketed	Vitamin C [EPC]	Egl nine homolog 1
Butanedioic Acid	SUCCINIC ACID		marketed	Vitamin C [EPC]	Egl nine homolog 1
VADADUSTAT	VADADUSTAT		marketed	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]		2023-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] class)

· 1 drug in this class
GSK · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Jesduvroq — Competitive Intelligence Brief. https://druglandscape.com/ci/daprodustat. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab